Regeneron in its bid to acquire substantially all of the assets of 23andMe for $256 million

On May 19, 2025, Regeneron Pharmaceuticals, Inc. announced that it has won the auction pursuant to Section 363 of the Bankruptcy Code to acquire substantially all of the assets of 23andMe for a purchase price of approximately $256 million. The acquisition is subject to the entry by the Bankruptcy Court of a sale order and the satisfaction of certain other closing conditions.

Wachtell, Lipton, Rosen & Katz is serving as legal advisor to Regeneron.